Investors

The BIRD Foundation has Approved an Additional Payment to Kadimastem and Miami Based iTolerance Inc. from the Total Grant for the Continued Co-Development of the Innovative Treatment for Diabetes

November 27, 2024 at 8:52:50 AM

Vote of Confidence by Major Kadimastem Shareholder in the Merger Transaction with Swiss Biopharma Company NLS Pharmaceutics

November 17, 2024 at 7:37:23 AM

NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement

November 5, 2024 at 7:34:17 AM

Kadimastem completes another stage towards the merger with NLS Pharmaceutics, which has Regained Full Compliance with Nasdaq Listing Requirements

October 29, 2024 at 8:05:32 AM

Kadimastem Ltd. and NLS Pharmaceutics Announce Binding Term Sheet to Merge

July 29, 2024 at 11:11:06 AM

The World Prestigious Diabetes Research Institute, University of Miami, Announces Kadimastem's Joint Project as Breakthrough Transplantation Approach for the Treatment of Type 1 Diabetes

June 23, 2024 at 7:08:03 AM

Kadimastem Takes Another Step Towards Signing the Merger Agreement with Nasdaq Listed IMCC

February 28, 2024 at 2:10:37 PM

Kadimastem advances towards Nasdaq: Company Signs a Memorandum of Understanding to Merge with a Company traded on the Nasdaq

February 14, 2024 at 10:00:00 PM

Kadimastem Receives Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes in India

February 7, 2024 at 10:44:02 AM

A peer reviewed article on Kadimastem's AstroRx® Cryopreserved off the Shelf Cell Product for the Treatment of ALS was Published in the Journal of Clinical Toxicology

January 24, 2024 at 10:00:00 PM

Kadimastem and iTolerance Complete Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting with the U.S. FDA

January 22, 2024 at 8:10:35 AM

Kadimastem and iTolerance Submit INTERACT Request with FDA for Potential Cure for Type 1 Diabetes

November 7, 2023 at 7:16:58 AM

Kadimastem Receives US Patent for Its Cell Selection & Enrichment Technology Used to Develop IsletRx

June 20, 2023 at 7:32:57 AM

Kadimastem Granted European Patent for Its IsletRx Treatment for Diabetes

May 15, 2023 at 11:10:42 AM

Kadimastem and iTolerance Sign Agreement and Receive US$1 Million from BIRD Foundation

May 9, 2023 at 6:16:05 AM

Kadimastem Earns FDA IND Approval For its US Phase IIa Clinical Trial with AstroRx® to Treat ALS

March 19, 2023 at 7:43:32 AM

Kadimastem Submits IND Application to the FDA for its Phase IIa Clinical Trial with AstroRx® for ALS

February 19, 2023 at 10:13:44 AM

Kadimastem's Clinical Trial in ALS Patients was Publicized in the Journal of Translational Medicine

February 15, 2023 at 10:16:24 AM

Awarded Patent in Australia for its AstroRx® Technology for the Treatment of ALS and Drug Screening

February 5, 2023 at 8:15:19 AM

Kadimastem Announces it raised appx 7.5 million NIS by rights offering

January 9, 2023 at 2:19:09 PM

Kadimastem and iTolerance’s Proposed Collaboration With Receipt of US $1 Million BIRD Grant

December 20, 2022 at 9:55:35 AM

Kadimastem Receives Approval of Patent registration Used to Develop IsletRx for Diabetes

September 28, 2022 at 6:47:50 AM

Kadimastem Receives US Patent For Amyotrophic Lateral Sclerosis (ALS) Treatment

August 9, 2022 at 7:36:45 AM

Kadimastem and Implant Therapeutics, Inc. Sign an Evaluation Agreement

June 8, 2022 at 6:24:04 AM

Kadimastem Awarded Patent in Japan for AstroRx® For ALS and Drug Screening

May 30, 2022 at 12:56:40 PM

Kadimastem Expands R&D Program to Include Multiple Sclerosis

May 17, 2022 at 9:00:00 PM

Kadimastem Receives Grant for a Total Budget of $3.1 million from the Israeli Innovation Authority

March 3, 2022 at 1:08:29 PM

Kadimastem Announces the Approval of a 4M NIS ($1.29M) Budget from the Israel Innovation Authority

December 13, 2021 at 10:36:37 AM

ILEX Medical to Invest 10 million NIS ($3.2 million)

November 29, 2021 at 12:20:17 PM

We rang the TASE bell today!

November 15, 2021 at 6:28:17 AM

Kadimastem Raises NIS 16.1 million ($5 million) In Private Placement

October 26, 2021 at 5:52:59 AM

Successful Meeting with the FDA (INTERACT) Regarding IsletRx for the Treatment of Diabetes

October 12, 2021 at 1:45:54 PM

Patent for Cell Selection of Beta Cells to Treat and Potentially Cure Diabetes was Granted in Japan

July 21, 2021 at 12:46:30 PM

Kadimastem Announces Publication in Frontiers in Endocrinology of a Peer-Reviewed Article

May 11, 2021 at 11:30:15 AM

Kadimastem Raises NIS 22.3 Million ($6.8 Million)

April 26, 2021 at 7:19:04 AM

Kadimastem Granted a Patent in Israel for the Treatment of ALS

March 9, 2021 at 9:00:16 AM

Kadimastem Announces Executive Management Changes

January 31, 2021 at 10:59:20 AM

Encouraging Results of Cohort B of its Phase 1/2a Clinical Trial of AstroRx® for ALS

December 15, 2020 at 1:56:27 PM

Kadimastem Reports Positive Interim Results of Cohort B of its AstroRx® Phase 1/2a Clinical Trial in

August 3, 2020 at 7:11:53 AM

Kadimastem Announces Promising Results of Cohort A of its Phase 1/2a Clinical Trial in ALS

July 27, 2020 at 1:25:35 PM

Kadimastem Announces the Completion of Treatment for Cohort B

July 27, 2020 at 1:25:54 PM

Successful Preclinical results of our Cell Therapy Treatment for Insulin-Dependent Diabetes

July 27, 2020 at 1:27:08 PM

Kadimastem to Submit an Amendment of its ALS Phase 1/2a Clinical Trial Protocol

July 27, 2020 at 1:28:11 PM

Kadimastem to Present at the 7th International Stem Cell Meeting, in Tel-Aviv

November 17, 2019 at 2:10:12 PM

Kadimastem Announces Promising Interim Results of Cohort A of its Phase 1/2a Clinical Trial in ALS

July 27, 2020 at 1:30:03 PM

Kadimastem Announces Leadership Changes

May 20, 2019 at 1:09:25 PM

Kadimastem receives Approval from the Ministry of Health of Israel to continue its trial of AstroRX®

April 18, 2019 at 1:45:49 PM

Appointment of a new CFO for Kadimastem

March 3, 2019 at 7:44:59 AM

Kadimastem Announces the Completion of Cell Transplantation of AstroRx® in ALS Patients for Cohort A

February 24, 2019 at 7:48:37 AM

2019 Israel Innovation Authority Budget Approved for Kadimastem: NIS 13.6 M for ALS Project

February 17, 2019 at 8:00:17 AM